Exosome removal as a therapeutic adjuvant in cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Whiteside TL: Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006, 16: 3-15. 10.1016/j.semcancer.2005.07.008.
Keller S, Sanderson MP, Stoeck A, Altevogt P: Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006, 107: 102-108. 10.1016/j.imlet.2006.09.005.
Fevrier B, Raposo G: Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol. 2004, 16: 415-421. 10.1016/j.ceb.2004.06.003.
de Gassart A, Geminard C, Hoekstra D, Vidal M: Exosome secretion: the art of reutilizing nonrecycled proteins?. Traffic. 2004, 5: 896-903. 10.1111/j.1600-0854.2004.00223.x.
Thery C, Zitvogel L, Amigorena S: Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002, 2: 569-579.
Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G: The biogenesis and functions of exosomes. Traffic. 2002, 3: 321-330. 10.1034/j.1600-0854.2002.30502.x.
Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A: Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem. 2009, 284: 34211-34222. 10.1074/jbc.M109.041152.
Koumangoye RB, Sakwe AM, Goodwin JS, Patel T, Ochieng J: Detachment of breast tumor cells induces rapid secretion of exosomes which subsequently mediate cellular adhesion and spreading. PLoS One. 2011, 6: e24234-10.1371/journal.pone.0024234.
Simpson RJ, Lim JW, Moritz RL, Mathivanan S: Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics. 2009, 6: 267-283. 10.1586/epr.09.17.
Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, Rank A, Gohring P, Thaler CJ, Friese K, Bauerfeind I: Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res. 2008, 28: 1107-1112.
Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008, 110: 13-21. 10.1016/j.ygyno.2008.04.033.
Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT, Carter BS, Krichevsky AM, Breakefield XO: Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008, 10: 1470-1476. 10.1038/ncb1800.
Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO, Widmark A: Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009, 100: 1603-1607. 10.1038/sj.bjc.6605058.
Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A: Can urinary exosomes act as treatment response markers in prostate cancer?. J Transl Med. 2009, 7: 4-10.1186/1479-5876-7-4.
Taylor DD, Taylor CG, Jiang CG, Black PH: Characterization of plasma membrane shedding from murine melanoma cells. Int J Cancer. 1988, 41: 629-635. 10.1002/ijc.2910410425.
Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, Perdicchio M, Marino ML, Federici C, Iessi E: High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009, 4: e5219-10.1371/journal.pone.0005219.
Taylor DD, Lyons KS, Gercel-Taylor C: Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol. 2002, 84: 443-448. 10.1006/gyno.2001.6551.
Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH: Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009, 10: 42-46. 10.3816/CLC.2009.n.006.
Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med. 1996, 183: 1161-1172. 10.1084/jem.183.3.1161.
Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S: Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med. 1998, 4: 594-600. 10.1038/nm0598-594.
Pan BT, Johnstone RM: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983, 33: 967-978. 10.1016/0092-8674(83)90040-5.
Sheng H, Hassanali S, Nugent C, Wen L, Hamilton-Williams E, Dias P, Dai YD: Insulinoma-released exosomes or microparticles are immunostimulatory and can activate autoreactive T cells spontaneously developed in nonobese diabetic mice. J Immunol. 2011, 187: 1591-1600. 10.4049/jimmunol.1100231.
Giri PK, Schorey JS: Exosomes derived from M. Bovis BCG infected macrophages activate antigen-specific CD4+ and CD8+ T cells in vitro and in vivo. PLoS One. 2008, 3: e2461-10.1371/journal.pone.0002461.
Beauvillain C, Juste MO, Dion S, Pierre J, Dimier-Poisson I: Exosomes are an effective vaccine against congenital toxoplasmosis in mice. Vaccine. 2009, 27: 1750-1757. 10.1016/j.vaccine.2009.01.022.
Bhatnagar S, Schorey JS: Exosomes released from infected macrophages contain Mycobacterium avium glycopeptidolipids and are proinflammatory. J Biol Chem. 2007, 282: 25779-25789. 10.1074/jbc.M702277200.
Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T: Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One. 2009, 4: e4942-10.1371/journal.pone.0004942.
Viaud S, Thery C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N: Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res. 2010, 70: 1281-1285. 10.1158/0008-5472.CAN-09-3276.
Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jeze G: Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006, 176: 2722-2729.
Andre F, Schartz NE, Chaput N, Flament C, Raposo G, Amigorena S, Angevin E, Zitvogel L: Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine. 2002, 20 (Suppl 4): A28-31.
Ichim TE, Zhong R, Min WP: Prevention of allograft rejection by in vitro generated tolerogenic dendritic cells. Transpl Immunol. 2003, 11: 295-306. 10.1016/S0966-3274(03)00048-0.
Popov I, Li M, Zheng X, San H, Zhang X, Ichim TE, Suzuki M, Feng B, Vladau C, Zhong R: Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Ther. 2006, 8: R141-10.1186/ar2031.
Luketic L, Delanghe J, Sobol PT, Yang P, Frotten E, Mossman KL, Gauldie J, Bramson J, Wan Y: Antigen presentation by exosomes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol. 2007, 179: 5024-5032.
Segura E, Amigorena S, Thery C: Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis. 2005, 35: 89-93. 10.1016/j.bcmd.2005.05.003.
Ruffner MA, Kim SH, Bianco NR, Francisco LM, Sharpe AH, Robbins PD: B7-1/2, but not PD-L1/2 molecules, are required on IL-10-treated tolerogenic DC and DC-derived exosomes for in vivo function. Eur J Immunol. 2009, 39: 3084-3090. 10.1002/eji.200939407.
Yang X, Meng S, Jiang H, Zhu C, Wu W: Exosomes derived from immature bone marrow dendritic cells induce tolerogenicity of intestinal transplantation in rats. J Surg Res. 2011, 171: 826-832. 10.1016/j.jss.2010.05.021.
Peche H, Renaudin K, Beriou G, Merieau E, Amigorena S, Cuturi MC: Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. Am J Transplant. 2006, 6: 1541-1550. 10.1111/j.1600-6143.2006.01344.x.
Kim SH, Bianco NR, Shufesky WJ, Morelli AE, Robbins PD: MHC class II + exosomes in plasma suppress inflammation in an antigen-specific and Fas ligand/Fas-dependent manner. J Immunol. 2007, 179: 2235-2241.
Ernerudh J, Berg G, Mjosberg J: Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. Am J Reprod Immunol. 2011, 66 (Suppl 1): 31-43.
Lin QD, Qiu LH: Pathogenesis, diagnosis, and treatment of recurrent spontaneous abortion with immune type. Front Med China. 2010, 4: 275-279. 10.1007/s11684-010-0101-y.
Pandey MK, Rani R, Agrawal S: An update in recurrent spontaneous abortion. Arch Gynecol Obstet. 2005, 272: 95-108. 10.1007/s00404-004-0706-y.
Frangsmyr L, Baranov V, Nagaeva O, Stendahl U, Kjellberg L, Mincheva-Nilsson L: Cytoplasmic microvesicular form of Fas ligand in human early placenta: switching the tissue immune privilege hypothesis from cellular to vesicular level. Mol Hum Reprod. 2005, 11: 35-41.
Taylor DD, Akyol S, Gercel-Taylor C: Pregnancy-associated exosomes and their modulation of T cell signaling. J Immunol. 2006, 176: 1534-1542.
Sabapatha A, Gercel-Taylor C, Taylor DD: Specific isolation of placenta-derived exosomes from the circulation of pregnant women and their immunoregulatory consequences. Am J Reprod Immunol. 2006, 56: 345-355. 10.1111/j.1600-0897.2006.00435.x.
Mincheva-Nilsson L, Nagaeva O, Chen T, Stendahl U, Antsiferova J, Mogren I, Hernestal J, Baranov V: Placenta-derived soluble MHC class I chain-related molecules down-regulate NKG2D receptor on peripheral blood mononuclear cells during human pregnancy: a possible novel immune escape mechanism for fetal survival. J Immunol. 2006, 176: 3585-3592.
Hedlund M, Stenqvist AC, Nagaeva O, Kjellberg L, Wulff M, Baranov V, Mincheva-Nilsson L: Human placenta expresses and secretes NKG2D ligands via exosomes that down-modulate the cognate receptor expression: evidence for immunosuppressive function. J Immunol. 2009, 183: 340-351. 10.4049/jimmunol.0803477.
Forger F, Marcoli N, Gadola S, Moller B, Villiger PM, Ostensen M: Pregnancy induces numerical and functional changes of CD4 + CD25 high regulatory T cells in patients with rheumatoid arthritis. Ann Rheum Dis. 2008, 67: 984-990.
Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H: Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008, 151: 235-243.
Gatson NN, Williams JL, Powell ND, McClain MA, Hennon TR, Robbins PD, Whitacre CC: Induction of pregnancy during established EAE halts progression of CNS autoimmune injury via pregnancy-specific serum factors. J Neuroimmunol. 2011, 230: 105-113. 10.1016/j.jneuroim.2010.09.010.
Weiner HL, da Cunha AP, Quintana F, Wu H: Oral tolerance. Immunol Rev. 2011, 241: 241-259. 10.1111/j.1600-065X.2011.01017.x.
Wei W, Zhang LL, Xu JH, Xiao F, Bao CD, Ni LQ, Li XF, Wu YQ, Sun LY, Zhang RH: A multicenter, double-blind, randomized, controlled phase III clinical trial of chicken type II collagen in rheumatoid arthritis. Arthritis Res Ther. 2009, 11: R180-10.1186/ar2870.
Benson JM, Stuckman SS, Cox KL, Wardrop RM, Gienapp IE, Cross AH, Trotter JL, Whitacre CC: Oral administration of myelin basic protein is superior to myelin in suppressing established relapsing experimental autoimmune encephalomyelitis. J Immunol. 1999, 162: 6247-6254.
Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H: Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997, 835: 120-131. 10.1111/j.1749-6632.1997.tb48623.x.
Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, Telemo E: "Tolerosomes" are produced by intestinal epithelial cells. Eur J Immunol. 2001, 31: 2892-2900. 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I.
Ostman S, Taube M, Telemo E: Tolerosome-induced oral tolerance is MHC dependent. Immunology. 2005, 116: 464-476.
Almqvist N, Lonnqvist A, Hultkrantz S, Rask C, Telemo E: Serum-derived exosomes from antigen-fed mice prevent allergic sensitization in a model of allergic asthma. Immunology. 2008, 125: 21-27. 10.1111/j.1365-2567.2008.02812.x.
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007, 9: 654-659. 10.1038/ncb1596.
Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z: Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol. 2011, 187: 676-683. 10.4049/jimmunol.1003884.
Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL: Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res. 2005, 11: 1010-1020.
Kim SH, Bianco N, Menon R, Lechman ER, Shufesky WJ, Morelli AE, Robbins PD: Exosomes derived from genetically modified DC expressing FasL are anti-inflammatory and immunosuppressive. Mol Ther. 2006, 13: 289-300. 10.1016/j.ymthe.2005.09.015.
Abusamra AJ, Zhong Z, Zheng X, Li M, Ichim TE, Chin JL, Min WP: Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis. Blood Cells Mol Dis. 2005, 35: 169-173. 10.1016/j.bcmd.2005.07.001.
Peng P, Yan Y, Keng S: Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep. 2011, 25: 749-762.
Monleon I, Martinez-Lorenzo MJ, Monteagudo L, Lasierra P, Taules M, Iturralde M, Pineiro A, Larrad L, Alava MA, Naval J, Anel A: Differential secretion of Fas ligand- or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J Immunol. 2001, 167: 6736-6744.
Bergmann C, Strauss L, Wieckowski E, Czystowska M, Albers A, Wang Y, Zeidler R, Lang S, Whiteside TL: Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression. Head Neck. 2009, 31: 371-380. 10.1002/hed.20968.
Taylor DD, Gercel-Taylor C: Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005, 92: 305-311.
Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL: T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003, 9: 5113-5119.
Cheriyan VT, Krishna SM, Kumar A, Jayaprakash PG, Balaram P: Signaling defects and functional impairment in T-cells from cervical cancer patients. Cancer Biother Radiopharm. 2009, 24: 667-673. 10.1089/cbr.2009.0660.
Zielinski P, Dyszkiewicz W, Piwkowski CT, Dworacki G, Gasiorowski L: Can the condition of the cell microenvironment of mediastinal lymph nodes help predict the risk of metastases in non-small cell lung cancer?. Cancer Epidemiol. 2009, 33: 387-390. 10.1016/j.canep.2009.10.011.
Kulkarni DP, Wadia PP, Pradhan TN, Pathak AK, Chiplunkar SV: Mechanisms involved in the down-regulation of TCR zeta chain in tumor versus peripheral blood of oral cancer patients. Int J Cancer. 2009, 124: 1605-1613. 10.1002/ijc.24137.
Gruber IV, El Yousfi S, Durr-Storzer S, Wallwiener D, Solomayer EF, Fehm T: Down-regulation of CD28, TCR-zeta (zeta) and up-regulation of FAS in peripheral cytotoxic T-cells of primary breast cancer patients. Anticancer Res. 2008, 28: 779-784.
Dworacki G, Meidenbauer N, Kuss I, Hoffmann TK, Gooding W, Lotze M, Whiteside TL: Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res. 2001, 7: 947s-957s.
Whiteside TL: Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother. 1999, 48: 346-352. 10.1007/s002620050585.
Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol. 2001, 166: 678-689.
Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI: All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006, 66: 9299-9307. 10.1158/0008-5472.CAN-06-1690.
Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009, 58: 49-59. 10.1007/s00262-008-0523-4.
Xiang X, Poliakov A, Liu C, Liu Y, Deng ZB, Wang J, Cheng Z, Shah SV, Wang GJ, Zhang L: Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer. 2009, 124: 2621-2633. 10.1002/ijc.24249.
Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010, 120: 457-471.
Janikashvili N, Bonnotte B, Katsanis E, Larmonier N: The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance. Clin Dev Immunol. 2011, 2011: 430394-
Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007, 178: 6867-6875.
Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L: Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. Cancer Res. 2006, 66: 9290-9298. 10.1158/0008-5472.CAN-06-1819.
Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P: The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010, 10: 554-567. 10.1038/nri2808.
Wada J, Onishi H, Suzuki H, Yamasaki A, Nagai S, Morisaki T, Katano M: Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res. 2010, 30: 3747-3757.
Wieckowski EU, Visus C, Szajnik M, Szczepanski MJ, Storkus WJ, Whiteside TL: Tumor-derived microvesicles promote regulatory T cell expansion and induce apoptosis in tumor-reactive activated CD8+ T lymphocytes. J Immunol. 2009, 183: 3720-3730. 10.4049/jimmunol.0900970.
Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL: Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One. 2010, 5: e11469-10.1371/journal.pone.0011469.
Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, Knoblaugh S, Cado D, Greenberg NM, Raulet DH: NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008, 28: 571-580. 10.1016/j.immuni.2008.02.016.
Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003, 3: 781-790. 10.1038/nri1199.
Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005, 436: 1186-1190. 10.1038/nature03884.
Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, Galloway DA, Gu W, Gautier J, Dalla-Favera R: Non-transcriptional control of DNA replication by c-Myc. Nature. 2007, 448: 445-451. 10.1038/nature05953.
Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002, 419: 734-738. 10.1038/nature01112.
Clayton A, Tabi Z: Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis. 2005, 34: 206-213. 10.1016/j.bcmd.2005.03.003.
Clayton A, Mitchell JP, Court J, Linnane S, Mason MD, Tabi Z: Human tumor-derived exosomes down-modulate NKG2D expression. J Immunol. 2008, 180: 7249-7258.
Ashiru O, Boutet P, Fernandez-Messina L, Aguera-Gonzalez S, Skepper JN, Vales-Gomez M, Reyburn HT: Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res. 2010, 70: 481-489. 10.1158/0008-5472.CAN-09-1688.
Hedlund M, Nagaeva O, Kargl D, Baranov V, Mincheva-Nilsson L: Thermal- and oxidative stress causes enhanced release of NKG2D ligand-bearing immunosuppressive exosomes in leukemia/lymphoma T and B cells. PLoS One. 2011, 6: e16899-10.1371/journal.pone.0016899.
Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004, 172: 7335-7340.
Fernandez-Messina L, Ashiru O, Boutet P, Aguera-Gonzalez S, Skepper JN, Reyburn HT, Vales-Gomez M: Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem. 2010, 285: 8543-8551. 10.1074/jbc.M109.045906.
Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, Waterfield MD, Ullrich A, Schlessinger J: Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985, 313: 144-147. 10.1038/313144a0.
Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS: The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005, 6: 243-257. 10.2174/1389450053765879.
Wang SE, Yu Y, Criswell TL, Debusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL: Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators. Oncogene. 2010, 29: 3335-3348. 10.1038/onc.2010.112.
Yasumoto K, Yamada T, Kawashima A, Wang W, Li Q, Donev IS, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S: The EGFR ligands amphiregulin and heparin-binding egf-like growth factor promote peritoneal carcinomatosis in CXCR4-expressing gastric cancer. Clin Cancer Res. 2011, 17: 3619-3630. 10.1158/1078-0432.CCR-10-2475.
Koga K, Matsumoto K, Akiyoshi T, Kubo M, Yamanaka N, Tasaki A, Nakashima H, Nakamura M, Kuroki S, Tanaka M, Katano M: Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res. 2005, 25: 3703-3707.
Battke C, Ruiss R, Welsch U, Wimberger P, Lang S, Jochum S, Zeidler R: Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother. 2011, 60: 639-648. 10.1007/s00262-011-0979-5.
Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, Morelli D, Villa A, Mina PD, Menard S: Potential role of HER2-overexpressing exosomes in countering Trastuzumab-based therapy. J Cell Physiol. 2012, 227: 658-667. 10.1002/jcp.22773.
Adamczyk KA, Klein-Scory S, Tehrani MM, Warnken U, Schmiegel W, Schnolzer M, Schwarte-Waldhoff I: Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sci. 2011, 89: 304-312. 10.1016/j.lfs.2011.06.020.
Graner MW, Alzate O, Dechkovskaia AM, Keene JD, Sampson JH, Mitchell DA, Bigner DD: Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 2009, 23: 1541-1557. 10.1096/fj.08-122184.
Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, Rak J: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008, 10: 619-624. 10.1038/ncb1725.
Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, Czupryna A, Szczepanik A: Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010, 59: 841-850. 10.1007/s00262-009-0808-2.
Tagliabue E, Balsari A, Campiglio M, Pupa SM: HER2 as a target for breast cancer therapy. Expert Opin Biol Ther. 2010, 10: 711-724. 10.1517/14712591003689972.
Higginbotham JN, Demory Beckler M, Gephart JD, Franklin JL, Bogatcheva G, Kremers GJ, Piston DW, Ayers GD, McConnell RE, Tyska MJ, Coffey RJ: Amphiregulin exosomes increase cancer cell invasion. Curr Biol. 2011, 21: 779-786. 10.1016/j.cub.2011.03.043.
Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J: Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A. 2009, 106: 3794-3799. 10.1073/pnas.0804543106.
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006, 3: 269-280. 10.1038/ncponc0509.
Nahta R, Esteva FJ: HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res. 2006, 8: 215-10.1186/bcr1612.
Abdel-Razeq H, Marei L: Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics. 2011, 5: 87-94.
Von Minckwitz G, Loibl S, Untch M: What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer?. Oncology (Williston Park). 2012, 26: 20-26.
Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, Palla SL, Tokuda Y, Gonzalez-Angulo AM, Hortobagyi GN, Ueno NT:NT: Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors.J Clin Oncol. 2011,
Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, Weinhage T, Menck K, Hupfeld T, Koch R: Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci U S A. 2011, 108: 15336-15341. 10.1073/pnas.1102855108.
Safaei R, Larson BJ, Cheng TC, Gibson MA, Otani S, Naerdemann W, Howell SB: Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol Cancer Ther. 2005, 4: 1595-1604. 10.1158/1535-7163.MCT-05-0102.
Chen KG, Valencia JC, Lai B, Zhang G, Paterson JK, Rouzaud F, Berens W, Wincovitch SM, Garfield SH, Leapman RD: Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A. 2006, 103: 9903-9907. 10.1073/pnas.0600213103.
Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR: Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res. 2003, 63: 4331-4337.
Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L: Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ. 2008, 15: 80-88. 10.1038/sj.cdd.4402237.
Zhang HG, Kim H, Liu C, Yu S, Wang J, Grizzle WE, Kimberly RP, Barnes S: Curcumin reverses breast tumor exosomes mediated immune suppression of NK cell tumor cytotoxicity. Biochim Biophys Acta. 2007, 1773: 1116-1123. 10.1016/j.bbamcr.2007.04.015.
Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, Marra M, Lugini L, Logozzi M, Lozupone F: Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004, 96: 1702-1713. 10.1093/jnci/djh305.
De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M: pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010, 127: 207-219. 10.1002/ijc.25009.
Spugnini EP, Citro G, Fais S: Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010, 29: 44-10.1186/1756-9966-29-44.
Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B, Simons M: Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008, 319: 1244-1247. 10.1126/science.1153124.
Lentz MR: Continuous whole blood UltraPheresis procedure in patients with metastatic cancer. J Biol Response Mod. 1989, 8: 511-527.
Lentz MR: The role of therapeutic apheresis in the treatment of cancer: a review. Ther Apher. 1999, 3: 40-49. 10.1046/j.1526-0968.1999.00147.x.
Snyder HW, Henry DH, Messerschmidt GL, Mittelman A, Bertram J, Ambinder E, Kiprov D, Balint JP, MacKintosh FR, Hamburger M: Minimal toxicity during protein A immunoadsorption treatment of malignant disease: an outpatient therapy. J Clin Apher. 1991, 6: 1-10. 10.1002/jca.2920060102.
Snyder HW, Balint JP, Jones FR: Modulation of immunity in patients with autoimmune disease and cancer treated by extracorporeal immunoadsorption with PROSORBA columns. Semin Hematol. 1989, 26: 31-41.
Fennelly DW, Norton L, Sznol M, Hakes TB: A phase II trial of extracorporeal plasma immunoadsorption of patient plasma with PROSORBA columns for treating metastatic breast cancer. Cancer. 1995, 75: 2099-2102. 10.1002/1097-0142(19950415)75:8<2099::AID-CNCR2820750812>3.0.CO;2-I.
Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V: Reduction of hepatitis C virus using lectin affinity plasmapheresis in dialysis patients. Blood Purif. 2009, 27: 64-69.
Escrevente C, Keller S, Altevogt P, Costa J: Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer. 2011, 11: 108-10.1186/1471-2407-11-108.
Batista BS, Eng WS, Pilobello KT, Hendricks-Munoz KD, Mahal LK: Identification of a conserved glycan signature for microvesicles. J Proteome Res. 2011, 10: 4624-4633. 10.1021/pr200434y.
Hirabayashi J: Glycome 'fingerprints' provide definitive clues to HIV origins. Nat Chem Biol. 2009, 5: 198-199.
Tullis RH, Duffin RP, Zech M, Ambrus JL: Affinity hemodialysis for antiviral therapy. I. Removal of HIV-1 from cell culture supernatants, plasma, and blood. Ther Apher. 2002, 6: 213-220. 10.1046/j.1526-0968.2002.00407.x.
Tullis RH, Duffin RP, Zech M, Ambrus JL: Affinity hemodialysis for antiviral therapy. II. Removal of HIV-1 viral proteins from cell culture supernatants and whole blood. Blood Purif. 2003, 21: 58-63. 10.1159/000067865.
Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG, Zielinski CC: Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer. 1997, 73: 875-879. 10.1002/(SICI)1097-0215(19971210)73:6<875::AID-IJC19>3.0.CO;2-3.
Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, Pacifico E, Tofanetti FR, Sidoni A, Basurto C: Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol. 2008, 19: 883-890. 10.1093/annonc/mdm585.
Molina R, Auge JM, Escudero JM, Filella X, Zanon G, Pahisa J, Farrus B, Munoz M, Velasco M: Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value. Tumour Biol. 2010, 31: 171-180. 10.1007/s13277-010-0025-9.
Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF: Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers. 2004, 19: 14-22.
Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, Deregibus MC, Tetta C, Bussolati B, Camussi G: Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res. 2011, 71: 5346-5356. 10.1158/0008-5472.CAN-11-0241.